|
|
||||||||
University of Michigan Medical Center, Division of Nuclear Medicine, Department of Internal Medicine, Ann Arbor, Michigan
Correspondence: For correspondence and/or reprints, contact: Richard L. Wahl, MD, Division of Nuclear Medicine, University of Michigan Medical Center, 1500 E. Medical Center Drive, B1G412, Ann Arbor, MI 48109-0028.
ABSTRACT
Monoclonal antibodies (Mabs) with tumor specificity and 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) are increasingly being used in cancer imaging. To better understand the mechanism and location of their uptake in tumors, nude mice bearing HTB77 IP3 ovarian cancer xenografts were injected intravenously with 3H-2-fluoro-2-deoxy-D-glucose (3H-DG) or 14C-2-deoxy-D-glucose (14C-DG), with 125I-5G6.4, a Mab that was developed against the HTB77 IP3 cell line (specific Mab) or with 125I-UPC-10 (nonspecific Mab). Tumors were excised at 2 hr or 6 days postinjection and autoradiography was performed. In tumors from animals receiving the Mabs, the grains were concentrated mainly on tumor cells near connective tissue ridges bearing blood vessels at 2 hr postinjection. At 6 days postinjection, further penetration into the tumors was seen, but four times more grains were seen on the viable cancer cells in the tumors receiving the specific Mab than in those receiving the irrelevant Mab. The selective accumulation of 2-DG in viable cancer cells and the negligible concentration of 2-DG in necrotic areas may be preferable to tumor-specific Mabs in assessing the extent of viable tumor and treatment response. Knowledge of the localization of a tracer at the microscopic level is essential to the understanding of the signal depicted on nuclear images using either type of radiotracer.
This article has been cited by other articles:
![]() |
E. E. Stewart, X. Chen, J. Hadway, and T.-Y. Lee Correlation between Hepatic Tumor Blood Flow and Glucose Utilization in a Rabbit Liver Tumor Model Radiology, June 1, 2006; 239(3): 740 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L.J. Dearling, A. A. Flynn, J. Sutcliffe-Goulden, I. A. Petrie, R. Boden, A. J. Green, G. M. Boxer, R. H.J. Begent, and R. B. Pedley Analysis of the Regional Uptake of Radiolabeled Deoxyglucose Analogs in Human Tumor Xenografts J. Nucl. Med., January 1, 2004; 45(1): 101 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bos, J. J.M. van der Hoeven, E. van der Wall, P. van der Groep, P. J. van Diest, E. F.I. Comans, U. Joshi, G. L. Semenza, O. S. Hoekstra, A. A. Lammertsma, et al. Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography J. Clin. Oncol., January 15, 2002; 20(2): 379 - 387. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Burgman, J. A. O'Donoghue, J. L. Humm, and C. C. Ling Hypoxia-Induced Increase in FDG Uptake in MCF7 Cells J. Nucl. Med., January 1, 2001; 42(1): 170 - 175. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Graeber, N. C. Gupta, and G. F. Murray POSITRON EMISSION TOMOGRAPHIC IMAGING WITH FLUORODEOXYGLUCOSE IS EFFICACIOUS IN EVALUATING MALIGNANT PULMONARY DISEASE J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 719 - 727. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |